Barbara Gayle Duncan - Net Worth and Insider Trading
Barbara Gayle Duncan Net Worth
The estimated net worth of Barbara Gayle Duncan is at least $592,434 dollars as of 2024-04-19. Barbara Gayle Duncan is the Chief Accounting Officer of Intercept Pharmaceuticals Inc and owns about 30,661 shares of Intercept Pharmaceuticals Inc (ICPT) stock worth over $582,559. Barbara Gayle Duncan is the Director of Aevi Genomic Medicine Inc and owns about 59,524 shares of Aevi Genomic Medicine Inc (GNMX) stock worth over $9,875. Barbara Gayle Duncan is also the Director of Jounce Therapeutics Inc and owns about 0 shares of Jounce Therapeutics Inc (JNCE) stock worth over $0. Details can be seen in Barbara Gayle Duncan's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Barbara Gayle Duncan has not made any transactions after 2020-09-15 and currently still holds the listed stock(s).
Transaction Summary of Barbara Gayle Duncan
Barbara Gayle Duncan Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Barbara Gayle Duncan owns 10 companies in total, including Jounce Therapeutics Inc (JNCE) , Immunomedics Inc (IMMU) , and Adaptimmune Therapeutics PLC (ADAP) among others .
Click here to see the complete history of Barbara Gayle Duncan’s form 4 insider trades.
Insider Ownership Summary of Barbara Gayle Duncan
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| JNCE | Jounce Therapeutics Inc | 2020-09-15 | director |
| IMMU | Immunomedics Inc | 2020-10-23 | director |
| ADAP | Adaptimmune Therapeutics PLC | 2016-06-23 | director |
| OVID | Ovid Therapeutics Inc | 2017-06-14 | director |
| GNMX | Aevi Genomic Medicine Inc | 2020-02-03 | director |
| INVA | Innoviva Inc | 2016-11-18 | director |
| ICPT | Intercept Pharmaceuticals Inc | 2016-10-03 | Chief Financial Officer |
| AVIR | Atea Pharmaceuticals Inc | 2020-10-29 | director |
| FUSN | Fusion Pharmaceuticals Inc | 2020-10-30 | director |
| HALO | Halozyme Therapeutics Inc | 2023-02-03 | director |
Barbara Gayle Duncan Latest Holdings Summary
Barbara Gayle Duncan currently owns a total of 3 stocks. Among these stocks, Barbara Gayle Duncan owns 30,661 shares of Intercept Pharmaceuticals Inc (ICPT) as of October 3, 2016, with a value of $582,559 and a weighting of 98.33%. Barbara Gayle Duncan owns 59,524 shares of Aevi Genomic Medicine Inc (GNMX) as of October 17, 2017, with a value of $9,875 and a weighting of 1.67%. Barbara Gayle Duncan also owns 0 shares of Jounce Therapeutics Inc (JNCE) as of September 15, 2020, with a value of $0 and a weighting of 0%.
Latest Holdings of Barbara Gayle Duncan
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ICPT | Intercept Pharmaceuticals Inc | 2016-10-03 | 30,661 | 19.00 | 582,559 |
| GNMX | Aevi Genomic Medicine Inc | 2017-10-17 | 59,524 | 0.17 | 9,875 |
| JNCE | Jounce Therapeutics Inc | 2020-09-15 | 0 | 1.88 | 0 |
Holding Weightings of Barbara Gayle Duncan
Barbara Gayle Duncan Form 4 Trading Tracker
According to the SEC Form 4 filings, Barbara Gayle Duncan has made a total of 0 transactions in Intercept Pharmaceuticals Inc (ICPT) over the past 5 years. The most-recent trade in Intercept Pharmaceuticals Inc is the sale of 147 shares on October 3, 2016, which brought Barbara Gayle Duncan around $23,990.
According to the SEC Form 4 filings, Barbara Gayle Duncan has made a total of 0 transactions in Aevi Genomic Medicine Inc (GNMX) over the past 5 years. The most-recent trade in Aevi Genomic Medicine Inc is the acquisition of 59,524 shares on October 17, 2017, which cost Barbara Gayle Duncan around $75,000.
According to the SEC Form 4 filings, Barbara Gayle Duncan has made a total of 1 transactions in Jounce Therapeutics Inc (JNCE) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Jounce Therapeutics Inc is the sale of 10,000 shares on September 15, 2020, which brought Barbara Gayle Duncan around $100,000.
Insider Trading History of Barbara Gayle Duncan
- 1
Barbara Gayle Duncan Trading Performance
GuruFocus tracks the stock performance after each of Barbara Gayle Duncan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Barbara Gayle Duncan is 4.84%. GuruFocus also compares Barbara Gayle Duncan's trading performance to market benchmark return within the same time period. The performance of stocks bought by Barbara Gayle Duncan within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Barbara Gayle Duncan's insider trading performs compared to the benchmark.
Performance of Barbara Gayle Duncan
Average Return
2.42%
Outperforming Transactions
100%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 18.55 | 4.84 | 25 | 2.42 | -68.89 | |
| Relative Return to S&P 500(%) | 17.79 | -4.66 | 19.26 | -7.34 | -77.12 |
Barbara Gayle Duncan Ownership Network
Ownership Network List of Barbara Gayle Duncan
Ownership Network Relation of Barbara Gayle Duncan
Barbara Gayle Duncan Owned Company Details
What does Jounce Therapeutics Inc do?
Who are the key executives at Jounce Therapeutics Inc?
Barbara Gayle Duncan is the director of Jounce Therapeutics Inc. Other key executives at Jounce Therapeutics Inc include 10 percent owner Concentra Merger Sub, Inc. , 10 percent owner Concentra Biosciences, Llc , and director & CEO and President Richard /ca/ Murray .
Jounce Therapeutics Inc (JNCE) Insider Trades Summary
Over the past 18 months, Barbara Gayle Duncan made no insider transaction in Jounce Therapeutics Inc (JNCE). Other recent insider transactions involving Jounce Therapeutics Inc (JNCE) include a net sale of 84,298 shares made by Richard /ca/ Murray , a net purchase of 85,987 shares made by Kevin C Tang , and a net sale of 16,634 shares made by Hugh M Cole .
In summary, during the past 3 months, insiders sold 0 shares of Jounce Therapeutics Inc (JNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 124,313 shares of Jounce Therapeutics Inc (JNCE) were sold and 85,987 shares were bought by its insiders, resulting in a net sale of 38,326 shares.
Jounce Therapeutics Inc (JNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Jounce Therapeutics Inc Insider Transactions
Barbara Gayle Duncan Mailing Address
Above is the net worth, insider trading, and ownership report for Barbara Gayle Duncan. You might contact Barbara Gayle Duncan via mailing address: C/o Intercept Pharmaceuticals, Inc., 18 Desbrosses Street, New York Ny 10013.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
